Program
IBI355
A development code. Also written as “Part A - IBI355”.
Its studies are mostly in Sjogren's Syndrome, led by Innovent Biologics.
Furthest: phase 2, since Sep 13, 20264 company-led studies, 1 open or runningNext primary completion: Nov 1, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 41 open or running | phase 2since Sep 13, 2026 | Oct 26, 2023 | Nov 1, 2027phase 2 · NCT07836660 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 26, 2023First study: phase 1 study in Healthy SubjectsFirst studyNCT06110338 · 53 enrolled · China
- May 11, 2024Phase 1 study in HealthyNCT06416787 · 32 enrolled · China
- Jun 26, 2024Phase 1 study in Primary Sjögren's SyndromeNCT06484855 · 30 enrolled · China
- Sep 13, 2026Phase 2 study in Sjogren's SyndromePhase 2 reachedNCT07836660 · 198 planned · China
Ahead
- Nov 1, 2027Primary completion: phase 2 study in Sjogren's SyndromeNCT07836660
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07836660Sjogren's Syndrome · China | 2 | Not yet recruiting | Nov 1, 2027 | 198 |
| NCT06484855Primary Sjögren's Syndrome · China | 1 | Completed | Jun 21, 2025 | 30 |
| NCT06416787Healthy · China | 1 | Completed | Feb 26, 2025 | 32 |
| NCT06110338Healthy Subjects · China | 1 | Completed | Sep 20, 2024 | 53 |
How it is read
Names in the registry
- “IBI355”, 3 entries
- “Part A - IBI355”, 1 entry
Codes read as this program: IBI355.
Conditions, from the studies’ own filings
- Sjogren's Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.